Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Study sponsor: Corcept Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-08-23Actual
Enrollment · participants43Actual
Source updated2023-11-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.